Biogen reported total revenue of $2.6 billion for Q2 2025, reflecting a 7% increase year-over-year. The company reported a GAAP diluted EPS of $4.33, an 8% increase, and a Non-GAAP diluted EPS of $5.47, up 4% year-over-year. Key growth drivers included strong sales from Alzheimer's disease treatments, particularly LEQEMBI, which saw U.S. sales of approximately $63 million and global sales of around $160 million. Other notable revenue contributions came from SKYCLARYS and ZURZUVAE, with respective revenues of $130 million and $46 million, indicating significant growth in demand for these products. Biogen also announced advancements in its late-stage pipeline, including the initiation of Phase 3 studies for several treatments in rare diseases.
The company has raised its full-year 2025 guidance, now expecting Non-GAAP diluted EPS between $15.50 and $16.00, up from a previous range of $14.50 to $15.50. Total revenue is expected to remain flat year-over-year at constant currency, an improvement from prior expectations of a mid-single-digit decline. The guidance reflects strong performance in the first half of 2025, although Biogen anticipates increased competitive pressures in the second half, particularly for its multiple sclerosis products in Europe. The company plans to invest in R&D to support its clinical development activities, particularly in rare diseases, while also aiming for significant cost savings through its
linkJul 31, 2025 06:13:54
Biogen Inc. anticipates that its GAAP and non-GAAP results for the second quarter of 2025 will reflect approximately $46 million in acquired in-process research and development expenses. This expense is expected to reduce net income per diluted share by about $0.26. The company has started reporting these expenses as a separate line item in its financial statements, which include costs related to collaboration and license agreements.
The financial results for the quarter ending June 30, 2025, are still being finalized and may differ from the preliminary estimates provided. Biogen has noted that it does not forecast these expenses due to the inherent uncertainties surrounding their occurrence and timing. Investors are advised that the final results will be subject to closing procedures and could vary from the current estimates.
linkJul 07, 2025 16:10:34
Biogen announced its first quarter 2025 financial results, reporting total revenue of $2.4 billion, which is a 6% increase compared to the same period last year. The company's GAAP diluted earnings per share (EPS) was $1.64, while the Non-GAAP diluted EPS was $3.02. The results were influenced by a $165 million upfront payment to Stoke Therapeutics, impacting EPS by approximately $0.95. Notably, product revenue increased by 3% at constant currency, with significant contributions from new product launches in Alzheimer's disease and rare diseases. LEQEMBI and SKYCLARYS showed growth in sales, with LEQEMBI generating approximately $96 million globally in the first quarter.
Biogen updated its full-year 2025 financial guidance, projecting Non-GAAP diluted EPS to range from $14.50 to $15.50, reflecting the impact of the Stoke payment and favorable foreign exchange rates. The company anticipates a mid-single digit percentage decline in total revenue for 2025 compared to 2024, primarily due to expected declines in multiple sclerosis product revenue. Biogen's ongoing initiatives, including the
linkMay 01, 2025 06:52:09
On the downside, Biogen faced a decline in total revenue for the full year 2024, primarily driven by a decrease in multiple sclerosis product sales, which dropped by 7% year-over-year. The company anticipates further revenue decline in 2025, projecting a mid-single digit percentage drop compared to 2024. Moreover, Biogen's collaboration profit-sharing led to a net expense of about $57 million in Q4 2024. The company also announced the discontinuation of several drug development programs, including those for early Alzheimer's and Parkinson's diseases, indicating a strategic shift in their pipeline focus.
linkFeb 12, 2025 07:06:19
Biogen Inc. announced the upcoming retirement of Michael McDonnell, the Executive Vice President and Chief Financial Officer, effective February 28, 2025. McDonnell has been with Biogen since August 2020 and has played a key role in restructuring the company for sustainable growth, including overseeing strategic acquisitions and promoting financial discipline. The leadership expressed gratitude for his contributions during his tenure, highlighting his mentorship and leadership in the Fit for Growth program.
Robin Kramer, currently the Chief Accounting Officer, will succeed McDonnell as CFO. Kramer, who joined Biogen in 2018, brings extensive experience in finance and has worked closely with McDonnell on the company’s growth initiatives. While the transition is positioned as smooth and beneficial for Biogen's future, the announcement also marks the end of McDonnell's impactful leadership, raising questions about the future direction of the company under new financial leadership.
linkOct 30, 2024 16:45:53
Biogen's third quarter 2024 results showed a revenue of $2.5 billion, with notable gains in new product launches for Alzheimer's, rare diseases, and depression, which helped to mitigate a decline in multiple sclerosis product revenue. The company also highlighted successful milestones in its pipeline, including positive results for dapirolizumab pegol and FDA Breakthrough Therapy Designation for felzartamab, contributing to an increase in full-year financial guidance for Non-GAAP diluted EPS.
However, Biogen continues to face challenges, as total revenue decreased by 3% compared to the previous year, primarily due to a decline in multiple sclerosis product sales. The company maintained its expectation of a low-single digit percentage decline in total revenue for the full year 2024. Additionally, the decision to halt further development of zuranolone for major depressive disorder adds to the negative outlook regarding future product offerings.
linkOct 30, 2024 06:55:17
Biogen Inc. has submitted a report detailing its financial statements, fulfilling regulatory requirements. This indicates the company's commitment to transparency and compliance with the Securities Exchange Act, which is a positive sign for investors and stakeholders.
The report includes an exhibit that may provide further insights into the company's financial health. However, the lack of specific financial performance details in this release leaves some uncertainty regarding its current market position.
linkAug 14, 2024 16:30:57
Biogen's second quarter 2024 results show solid growth, with total revenue of $2.5 billion and a significant increase in Non-GAAP EPS by 31%. The company reported strong performance in its pharmaceutical sector, particularly with the launch of LEQEMBI for Alzheimer's disease. Additionally, Biogen raised its full-year financial guidance, reflecting confidence in its ongoing strategies and product launches. However, GAAP diluted EPS saw a slight decline of 2%, indicating some challenges amidst the overall positive performance.
linkAug 01, 2024 06:55:02
Biogen's Q1 2024 shows 8% Non-GAAP EPS growth, LEQEMBI sales up significantly, SKYCLARYS launch progressing well. However, total revenue decreased by 7%, attributed to product revenue decline. The company reaffirms 2024 financial guidance, expecting EPS growth of 5% and operating income growth. Cost savings initiatives positively impacted margins. Biogen emphasizes progress in new product launches and commitment to sustainable growth and value creation.
linkApr 24, 2024 07:02:57
Biogen reported a decline in revenue for Q4 2023 and full year 2023, with a negative impact on EPS due to closeout costs for ADUHELM. The company expects a return to non-GAAP EPS growth in 2024, with a focus on operational execution and new product launches. Biogen plans to co-promote LEQEMBI in the U.S. and Japan, expand its rare disease portfolio, and generate significant savings by 2025 through its 'Fit for Growth' initiative.
linkFeb 13, 2024 07:07:23